Reza Mirfakhraie

Prof. Reza Mirfakhraie


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
MIMostafa Iranpour
Mostafa Iranpour
MSMohammad Soudyab
Mohammad Soudyab
LGLobat Geranpayeh
Lobat Geranpayeh
RMReza Mirfakhraie
Reza Mirfakhraie
EAEznollah Azargashb
Eznollah Azargashb
SGSoudeh Ghafouri-Fard
Soudeh Ghafouri-Fard

1 September 2016 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
SIShiva Irani
Shiva Irani
RMReza Mirfakhraie
Reza Mirfakhraie
AJAzam Jalili
Azam Jalili
Background: Current cancer treatments have unexpected side effects of which the death of normal cells is one. In some cancers, iron nanoparticles (NPs) can be subjected to diagnosis and passive targeting treatment. Cold atmospheric plasma (CAP) has a proven induction of selective cell death ability. In this study, we have attempted to analyze the synergy between CAP and iron NPs in human breast adenocarcinoma cells (MCF-7). Materials and methods: In vitro cytotoxicity of CAP treatment and NPs in cells measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cell death was shown by 4',6-diamidino-2-phenylindole and annexin V staining. Fluctuations in BAX and BCL-2 gene expression were investigated by means of real-time polymerase chain reaction. Results: MTT assay results showed that combination of plasma and iron NPs decreased the viability of cancer cells significantly (P<0.05). Real-time analysis showed that the combination therapy induced shifting the BAX/BCL-2 ratio in favor of apoptosis. Conclusion: Our data indicate that synergy between CAP and iron NPs can be applied in breast cancer treatment selectively.

1 August 2018
Verified
Journal Article
Open access
SBSara Bitarafan
Sara Bitarafan
MYMohsen Yari
Mohsen Yari
MBMohammad Ali Broumand
Mohammad Ali Broumand
SGSayyed Mohammad Hossein Ghaderian
Sayyed Mohammad Hossein Ghaderian
MRMahnoosh Rahimi
Mahnoosh Rahimi
MOMir Davood Omrani
Mir Davood Omrani
Objective: Considerable research shows that long non-coding RNAs, those longer than 200 nucleotides, are involved in several human diseases such as various cancers and cardiovascular diseases. Their significant role in regulating the function of endothelial cells, smooth muscle cells, macrophages, vascular inflammation, and metabolism indicates the possible effects of IncRNAs on the progression of atherosclerosis which is the most common underlying pathological process responsible for coronary artery disease (CAD). The aim of present study was to assess whether the expression of the Inc RNA H19 was associated with a susceptibility to CAD by evaluating the expression level of H19 in the peripheral blood. Materials and Methods: A case-control study of 50 CAD patients and 50 age and sex-matched healthy controls was undertaken to investigate whether the H19 IncRNA expression level is associated with a CAD using Taqman Real-Time polymerase chain reaction (PCR). Results: The subsequent result indicated that the H19 IncRNA was over-expressed in CAD patients in comparison with the controls. However, it was not statistically significant. This overexpression may be involved in coronary artery disease progression. Conclusion: We report here, the up-regulation of H19 IncRNA in the whole blood of CAD patients and suggest a possible role for H19 in the atherosclerosis process and its consideration as novel biomarker for CAD.

17 June 2016 in Autism Research
Verified
Journal Article
Closed access
PDF file
RNRezvan Noroozi
Rezvan Noroozi
Mohammad TaheriMohammad Taheri
Mohammad Taheri
AMAbolfazl Movafagh
Abolfazl Movafagh
RMReza Mirfakhraie
Reza Mirfakhraie
GSGhasem Solgi
Ghasem Solgi
HDHossein Darvish
Hossein Darvish

1 May 2016 in Genetic Testing and Molecular Biomarkers
Verified
Journal Article
Closed access
Milad BastamiMilad Bastami
Milad Bastami
SGSayyed Mohamad Hossein Ghaderian
Sayyed Mohamad Hossein Ghaderian
MOMir Davood Omrani
Mir Davood Omrani
RMReza Mirfakhraie
Reza Mirfakhraie
HVHossein Vakili
Hossein Vakili
Andrea MasottiAndrea Masotti
Andrea Masotti
Aims: Recent studies have suggested that single-nucleotide polymorphisms (SNPs) in miRNA genes or their binding sites may alter an individual's susceptibility to coronary artery disease (CAD). In the present study, the association between two such SNPs (rs2910164 in miR-146a and rs12190287, which disrupts miRNA binding to TCF21) and CAD, in an Iranian population, was evaluated and an in silico analyses were conducted to predict disease-related effects of miR-146a rs2910164. Methods: The study population consisted of angiographically confirmed CAD patients (n = 300) and asymptomatic controls (n = 300). Genotyping was performed using the TaqMan genotyping assay. Results: A multivariate regression analysis revealed that rs2910164 was associated with an increased CAD risk in the dominant model. In comparison to GG homozygotes, individuals who carry at least one C allele had a significantly higher risk of CAD (GC+CC vs. GG, odds ratios [OR]: 1.82, 95% confidence intervals [CI]: 1.18–2.80, p = 6.358e-3). Similarly, TCF21 rs12190287 was observed to be associated with CAD in a log-additive model (OR: 0.63, 95% CI: 0.45–0.88, p = 6.584e-3). An in silico analysis revealed that rs2910164 may modify the miR-146a-3p-mediated regulation of several biological processes that are implicated in CAD, like those that are related to the regulation of apoptosis and immune response. Conclusions: Our data provide the first evidence for the association of miR-146a rs2910164 and TCF21 rs12190287 with CAD in an Iranian population, encouraging further research to elucidate the disease-related effects of miR-146a rs2910164.

17 August 2016 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
ZMZahra H. Mirzaie
Zahra H. Mirzaie
SIShiva Irani
Shiva Irani
RMReza Mirfakhraie
Reza Mirfakhraie
SASeyed Mohammad Atyabi
Seyed Mohammad Atyabi
MDMeshkat Dinarvand
Meshkat Dinarvand
FAFatemeh Atyabi
Fatemeh Atyabi